Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug.

Harrison DB, Phillips AL, Tansey JB, Clarke TJ, Wood CB, Nedzi L, Schwartz DL, Makowski L, Hayes DN, Newman G, Gleysteen JP

The Laryngoscope7 Oct 2024Cited by 4 (Europe PMC)

PMID39370986 (opens in a new tab)PMCIDPMC11729570 (opens in a new tab)DOI10.1002/lary.31815 (opens in a new tab)PepBankPUB-39370986
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesOther

    In a woman with class III obesity treated with semaglutide, PET/CT showed extensive FDG uptake in brown adipose tissue of the neck and mediastinum that complicated the diagnosis of head and neck cancer.

    In plain wordsIn one woman taking semaglutide, brown fat took up a lot of the PET scan tracer, which made the scan look like cancer spread.

    Peptide
    Semaglutide
    Outcome
    IncreaseFDG uptake in brown adipose tissue on PET/CT
    Study

    n = 1

    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    PET/CT revealed FDG uptake in the right level II lymph node and extensive BAT uptake throughout the neck and mediastinum, complicating the diagnosis.
    2 context sentences
    Summary · context
    Increased FDG uptake in the cervical and supraclavicular BAT regions led to diagnostic confusion, mimicking diffuse regional metastasis.
    Summary · context
    A 61-year-old female with Class III obesity presented with a right-sided neck mass after significant weight loss following the use of the GLP-1 receptor agonist, Semaglutide.
  2. 02HumanCase report or seriesEfficacy outcome

    A woman with class III obesity had significant weight loss after using semaglutide.

    In plain wordsOne woman with severe obesity lost a lot of weight after using semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss after semaglutide use
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A 61-year-old female with Class III obesity presented with a right-sided neck mass after significant weight loss following the use of the GLP-1 receptor agonist, Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.